Comirnaty - first boost in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias confirmed COVID (any severity)detailed results C4591031- first boost, 2021 0.05 [0.02; 0.13]
0.05 [0.02 ; 0.13 ] C4591031- first boost, 2021 1 0% 10,125 NA not evaluable severe COVID-19 (FDA definition)detailed results C4591031- first boost, 2021 0.25 [0.01; 5.50]
0.25 [0.01 ; 5.50 ] C4591031- first boost, 2021 1 0% 10,125 NA not evaluable severe COVID-19 occurrencedetailed results C4591031- first boost, 2021 0.25 [0.01; 5.50]
0.25 [0.01 ; 5.50 ] C4591031- first boost, 2021 1 0% 10,125 NA not evaluable arrhythmiadetailed results C4591031- first boost, 2021 1.99 [0.07; 59.22]
1.99 [0.07 ; 59.22 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable hypertensiondetailed results C4591031- first boost, 2021 0.50 [0.02; 14.80]
0.50 [0.02 ; 14.80 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable Myocardial infarction detailed results C4591031- first boost, 2021 0.74 [0.17; 3.33]
0.74 [0.17 ; 3.33 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable pulmonary embolismdetailed results C4591031- first boost, 2021 0.17 [0.01; 3.30]
0.17 [0.01 ; 3.30 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable stroke (non-specific, hemorrhagic, and ischemic)detailed results C4591031- first boost, 2021 0.99 [0.06; 15.88]
0.99 [0.06 ; 15.88 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable cerebral venous sinus thrombosis (CVST)detailed results C4591031- first boost, 2021 0.50 [0.02; 14.80]
0.50 [0.02 ; 14.80 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable appendicitisdetailed results C4591031- first boost, 2021 3.97 [0.18; 88.14]
3.97 [0.18 ; 88.14 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 05:54 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 89
- treatments: 1330
- roots T: 290